$640 Million is the total value of Soleus Capital Management, L.P.'s 74 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OLK | Exit | OLINK HLDG ABsponsored ads | $0 | – | -53,961 | -100.0% | -0.12% | – |
| PCRX | Exit | PACIRA BIOSCIENCES INC | $0 | – | -22,250 | -100.0% | -0.22% | – |
| Exit | CYTEK BIOSCIENCES INC | $0 | – | -180,000 | -100.0% | -0.25% | – | |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -159,200 | -100.0% | -0.25% | – |
| LQDA | Exit | LIQUIDIA CORPORATION | $0 | – | -293,485 | -100.0% | -0.27% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEW | $0 | – | -69,000 | -100.0% | -0.30% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -7,800 | -100.0% | -0.30% | – |
| ARYD | Exit | ARYA SCIENCES ACQU CORP IVcl a | $0 | – | -300,000 | -100.0% | -0.38% | – |
| SIEN | Exit | SIENTRA INC | $0 | – | -1,641,337 | -100.0% | -0.47% | – |
| NEO | Exit | NEOGENOMICS INC | $0 | – | -460,000 | -100.0% | -0.72% | – |
| TXG | Exit | 10X GENOMICS INC | $0 | – | -106,139 | -100.0% | -1.04% | – |
| SNN | Exit | SMITH & NEPHEW PLCspdn adr new | $0 | – | -385,000 | -100.0% | -1.58% | – |
| HOLX | Exit | HOLOGIC INC | $0 | – | -225,600 | -100.0% | -2.24% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -3,055,193 | -100.0% | -2.67% | – |
| ILMN | Exit | ILLUMINA INC | $0 | – | -62,300 | -100.0% | -2.81% | – |
| XBI | Exit | SPDR SER TRcall | $0 | – | -1,408,100 | -100.0% | -16.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.